March 23, 2020 10:42 AM EDT
News Briefing

BEL­LUS Health buys IP rights, ban­ish­es roy­al­ties; Ab­b­Vie gets con­fir­ma­to­ry da­ta on ac­cel­er­at­ed AML drug

ENDPOINTS

→ Cana­da’s BEL­LUS Health $BLU has bagged the re­main­ing IP rights for its BLU-5937 and re­lat­ed P2X3 an­tag­o­nists. The deal scraps the tiered roy­al­ty pay­ments …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times